cecum neuroendocrine tumor G1

Summary

cecum neuroendocrine tumor G1 (MONDO:0006126) is a cancer and 3 clinical trials. Top therapeutic interventions include paltusotine. A subtype of cecal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cecum neuroendocrine tumor G1
Mondo ID	MONDO:0006126
NCIT	C5501
UMLS	C0854488
MedGen	167703
GARD	0024301
Anatomy (UBERON)	UBERON:0001153
Is cancer (heuristic)	yes

Also known as: caecal carcinoid tumor · caecal carcinoid tumour · caecum carcinoid tumor · caecum carcinoid tumor (disease) · caecum carcinoid tumour · caecum carcinoid tumour (disease) · caecum NET G1 · caecum neuroendocrine neoplasm G1 · caecum neuroendocrine tumor, well differentiated, low grade · carcinoid tumor of cecum · carcinoid tumor of the cecum · carcinoid tumour of cecum · carcinoid tumour of the cecum · cecal carcinoid tumor · cecal carcinoid tumour · cecum carcinoid tumor · cecum carcinoid tumour · cecum NET G1 · cecum neuroendocrine tumor G1 · grade 1 neuroendocrine neoplasm of caecum

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › cecal disorder › cecal neoplasm › cecum neuroendocrine tumor G1

Related subtypes (4): cecum villous adenoma, appendiceal neoplasm, cecum cancer, benign neoplasm of cecum

Subtypes (1): appendix neuroendocrine tumor G1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07087054	PHASE3	RECRUITING	Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT05361668	PHASE2	COMPLETED	Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
NCT04907643	Not specified	RECRUITING	Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALTUSOTINE	3	2